ATRS Antares Pharma Inc.

3.02
-0.09  -3%
Previous Close 3.11
Open 3.08
Price To Book 20.13
Market Cap 475774632
Shares 157,541,269
Volume 1,023,565
Short Ratio
Av. Daily Volume 1,543,294

SEC filingsSee all SEC filings

  1. 8-K - Current report 181232383
  2. 8-K - Current report 181185936
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163564
  4. 8-K - Current report 181161452
  5. 8-K - Current report 181099553

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
FDA Approval announced October 1, 2018.
XYOSTED (testosterone enanthate)
Testosterone deficiency

Latest News

  1. What Kind Of Shareholder Appears On The Antares Pharma, Inc.’s (NASDAQ:ATRS) Shareholder Register?
  2. Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
  3. ATRS: Xyosted & Epi Pen Available for Sale
  4. Should You Buy NanoString Technologies Inc (NSTG)?
  5. Is Noodles & Co (NDLS) A Good Stock To Buy?
  6. Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies — New Research Emphasizes Economic Growth
  7. Antares Pharma Announces the Commercial Availability of XYOSTED™ (Testosterone Enanthate) Injection — A New Treatment for Adult Men Diagnosed With Testosterone Deficiency
  8. Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
  9. Teva's generic EpiPen hits the market in limited doses
  10. Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen®
  11. ATRS: Xyosted Launch Before Year End
  12. Edited Transcript of ATRS earnings conference call or presentation 6-Nov-18 1:30pm GMT
  13. Healthcare Value Capital, LLC Buys Antares Pharma Inc, Sells Novelion Therapeutics Inc
  14. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Antares Pharma, Inc. (ATRS) and Encourages ATRS Investors to Contact the Firm
  15. Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to Class Action
  16. Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting
  17. Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference
  18. Antares Pharma: 3Q Earnings Snapshot
  19. Antares Pharma Reports Third Quarter 2018 Operating and Financial Results

SEC Filings

  1. 8-K - Current report 181232383
  2. 8-K - Current report 181185936
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163564
  4. 8-K - Current report 181161452
  5. 8-K - Current report 181099553
  6. 8-K - Current report 181057514
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998522
  8. 8-K - Current report 18996271
  9. 8-K - Current report 18899977
  10. 8-K - Current report 18880201